Company / Operating Income
SUTRO BIOPHARMA, INC. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$238.5M
FY2025
5-year range
-$238.5M / -$55.5M
FY2021-FY2025
Trend
-84.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 7 consecutive years, from $1M in FY2018 to -$238M in FY2025.
Based on SEC 10-K filings.
-$238M in FY2025.
Declined from -$99M to -$238M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s operating income has declined for 7 consecutive years.
- In FY2025, operating income decreased 84.9% year-over-year.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$238.5M | -84.9% |
| FY2024 | -$128.9M | -30.9% |
| FY2023 | -$98.5M | -38.7% |
| FY2022 | -$71.1M | -28.1% |
| FY2021 | -$55.5M | -49.0% |
| FY2020 | -$37.2M | -93.1% |
| FY2019 | -$19.3M | -1512.9% |
| FY2018 | $1.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026